Jennifer Sugg

6.3k total citations · 5 hit papers
66 papers, 4.6k citations indexed

About

Jennifer Sugg is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jennifer Sugg has authored 66 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Jennifer Sugg's work include Diabetes Treatment and Management (24 papers), Prostate Cancer Treatment and Research (22 papers) and Cancer, Lipids, and Metabolism (16 papers). Jennifer Sugg is often cited by papers focused on Diabetes Treatment and Management (24 papers), Prostate Cancer Treatment and Research (22 papers) and Cancer, Lipids, and Metabolism (16 papers). Jennifer Sugg collaborates with scholars based in United States, United Kingdom and Canada. Jennifer Sugg's co-authors include Shamik Parikh, John Wilding, Östen Ljunggren, Jan Bolinder, Anna Maria Langkilde, Lars Johansson, Joel Kullberg, C. David Sjöström, Neal D. Shore and Katja Rohwedder and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Jennifer Sugg

66 papers receiving 4.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

2012 694 citations John Wilding, Jennifer Sugg et al. profile →
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

2019 686 citations Andrew J. Armstrong, Arnauld Villers et al. profile →
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

2013 389 citations John Wilding, Jennifer Sugg et al. profile →
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020 266 citations Cora N. Sternberg, Karim Fizazi et al. New England Journal of Medicine profile →
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

2023 114 citations Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Sugg United States	26	2.8k	1.6k	1.5k	1.4k	572	66	4.6k
Matthew A. Cavender United States	28	4.7k 1.7×	2.0k 1.2×	2.1k 1.4×	370 0.3×	628 1.1×	86	6.7k
Sukrut Shah United States	25	1.0k 0.4×	500 0.3×	2.0k 1.4×	890 0.6×	125 0.2×	61	3.5k
David Kallend United States	36	2.6k 0.9×	1.5k 0.9×	5.4k 3.6×	454 0.3×	140 0.2×	99	7.8k
Michael C dʼEmden Australia	22	2.9k 1.0×	1.0k 0.6×	2.4k 1.6×	156 0.1×	190 0.3×	72	5.4k
Joerg Koglin United States	25	2.2k 0.8×	996 0.6×	2.5k 1.7×	821 0.6×	316 0.6×	47	5.6k
Carlos G. Santos‐Gallego United States	34	1.4k 0.5×	959 0.6×	1.1k 0.8×	390 0.3×	109 0.2×	97	3.2k
Boaz Hirshberg United States	41	6.2k 2.2×	2.7k 1.6×	3.5k 2.4×	603 0.4×	990 1.7×	118	8.7k
Alison J. Cox Australia	35	961 0.3×	1.2k 0.8×	485 0.3×	280 0.2×	238 0.4×	71	3.6k
Thomas A. Zelniker United States	21	6.8k 2.4×	2.8k 1.7×	2.8k 1.9×	1.3k 0.9×	748 1.3×	68	8.8k
Weichung Shih United States	17	2.0k 0.7×	1.0k 0.6×	820 0.6×	465 0.3×	265 0.5×	31	2.8k

Countries citing papers authored by Jennifer Sugg

Since Specialization

Citations

This map shows the geographic impact of Jennifer Sugg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Sugg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Sugg more than expected).

Fields of papers citing papers by Jennifer Sugg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Sugg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Sugg. The network helps show where Jennifer Sugg may publish in the future.

Co-authorship network of co-authors of Jennifer Sugg

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Sugg. A scholar is included among the top collaborators of Jennifer Sugg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Sugg. Jennifer Sugg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharifi, Nima, Arun Azad, Jason W.D. Hearn, et al.. (2024). HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES. Cell Reports Medicine. 5(8). 101644–101644. 4 indexed citations

Freedland, Stephen J., Murilo Luz, Ugo De Giorgi, et al.. (2023). Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 389(16). 1453–1465. 114 indexed citations breakdown →

Joshua, Anthony M., Andrew J. Armstrong, Megan Crumbaker, et al.. (2022). Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European Journal of Cancer. 170. 285–295. 21 indexed citations

Giorgi, Ugo De, Maha Hussain, Neal D. Shore, et al.. (2021). Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer. 159. 237–246. 8 indexed citations

Jankú, Filip, Patricia LoRusso, Aaron S. Mansfield, et al.. (2021). First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Investigational New Drugs. 39(5). 1348–1356. 27 indexed citations

Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, et al.. (2021). Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer and Prostatic Diseases. 25(2). 363–365. 7 indexed citations

Rohwedder, Katja, et al.. (2014). Change in quality of life (EQ-5D) among type 2 diabetes mellitus patients inadequately controlled with metformin plus sulfonylurea and treated with dapagliflozin as triple therapy regimen for 24 weeks. Value in Health. 17(3). A257–A257. 1 indexed citations

Bujac, Sarah R., Angelo Del Parigi, Jennifer Sugg, et al.. (2014). Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data. Diabetes Therapy. 5(2). 471–482. 10 indexed citations

Johnsson, Kristina, et al.. (2013). Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. Journal of Diabetes and its Complications. 27(5). 479–484. 173 indexed citations

10.

Johnsson, Kristina, et al.. (2013). Urinary tract infections in patients with diabetes treated with dapagliflozin. Journal of Diabetes and its Complications. 27(5). 473–478. 170 indexed citations

11.

Karlson, Björn W., et al.. (2013). A Pharmacokinetic and Pharmacodynamic Comparison of Immediate-Release Metoprolol and Extended-Release Metoprolol CR/XL in Patients with Suspected Acute Myocardial Infarction: A Randomized, Open-Label Study. Cardiology. 127(2). 73–82. 4 indexed citations

12.

Wilding, John, et al.. (2012). Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin. Annals of Internal Medicine. 25 indexed citations

13.

Schaefer, Franz, Johan Van de Walle, Aleksandra Żurowska, et al.. (2010). Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Journal of Hypertension. 28(5). 1083–1090. 47 indexed citations

14.

Trachtman, Howard, James W. Hainer, Jennifer Sugg, et al.. (2008). Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Children Aged 6 to 17 Years. Journal of Clinical Hypertension. 10(10). 743–750. 51 indexed citations

15.

Colucci, Wilson S., Theodore J. Kolias, Kirkwood F. Adams, et al.. (2007). Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction. Circulation. 116(1). 49–56. 121 indexed citations

16.

Batisky, Donald L., Jonathan M. Sorof, Jennifer Sugg, et al.. (2007). Efficacy and Safety of Extended Release Metoprolol Succinate in Hypertensive Children 6 to 16 Years of Age: A Clinical Trial Experience. The Journal of Pediatrics. 150(2). 134–139.e1. 45 indexed citations

17.

Frishman, William H., et al.. (2006). A Factorial Study of Combination Hypertension Treatment With Metoprolol Succinate Extended Release and Felodipine Extended ReleaseResults of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). American Journal of Hypertension. 19(4). 388–395. 27 indexed citations

18.

Papademetriou, Vasilios, et al.. (2006). Factorial Antihypertensive Study of an Extended-Release Metoprolol and Hydrochlorothiazide Combination. American Journal of Hypertension. 19(12). 1217–1225. 17 indexed citations

19.

Laine, Loren & Jennifer Sugg. (2002). Effect of Helicobacter pylori Eradication on Development of Erosive Esophagitis and Gastroesophageal Reflux Disease Symptoms: A Post Hoc Analysis of Eight Double Blind Prospective Studies. The American Journal of Gastroenterology. 97(12). 2992–2997. 105 indexed citations

20.

Laine, Loren, Brian Fennerty, Michael S. Osato, et al.. (2000). Esomeprazole-Based Helicobacter Pylori Eradication Therapy and The Effect of Antibiotic Resistance: Results of Three Us Multicenter, Double-Blind Trials. The American Journal of Gastroenterology. 95(12). 3393–3398. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact